MUMBAI, India, Aug. 22 -- Intellectual Property India has published a patent application (202517067361 A) filed by Nanexa Ab, Uppsala, Sweden, on July 15, for 'new pharmaceutical compositions comprising glucagon-like peptide-1 receptor agonists.'
Inventor(s) include Johansson, Anders; Rooth, Marten; Hellrup, Joel; Westberg, David; Lindahl, Erik; Hedge, Oliver; and Rouf, Polla.
The application for the patent was published on Aug. 22, under issue no. 34/2025.
According to the abstract released by the Intellectual Property India: "There is provided a pharmaceutical formulation that is useful in the treatment of metabolic disorders or conditions, comprising a plurality of particles suspended in a carrier system, which particles: (a) have a weight-, number-, or volume-based mean diameter that is between amount 10 nm and about 700 m; and (b) comprise solid cores comprising at least one glucagon-like peptide-1 receptor agonist, or a pharmaceutically-acceptable salt thereof, coated, at least in part, by a coating of inorganic material comprising mixture of: (i) zinc oxide; and (ii) one or more other metal and/or metalloid oxides, wherein the atomic ratio ((i):(ii)) is at least about 1:10 and up to and including about 10:1. Said mixed oxide coated particles are preferably synthesized via a gas phase coating technique, such as atomic layer deposition. The formulation may provide for the delayed or sustained release of glucagon-like peptide-1 receptor agonists to treat metabolic disorders or conditions, such as type 2 diabetes and/or obesity without a burst effect. The glucagon-like peptide-1 receptor agonist is preferably liraglutide."
The patent application was internationally filed on Dec. 14, 2023, under International application No.PCT/GB2023/053232.
Disclaimer: Curated by HT Syndication.
